A catalogue of missense and nonsense mutation abundances for the U.S. cancer patient population
Arun, A.; Liarakos, D.; Mendiratta, G.; McFall, T.; Hargreaves, D. C.; Wahl, G. M.; Hu, J.; Stites, E. C.
Show abstract
Widespread genomic sequencing efforts have characterized the molecular foundations of the different cancers. By combining these genomic data in a manner proportional to the population-level abundances of these different cancers, we estimate the overall abundances of each observed missense and nonsense mutation within the U.S. cancer patient population. We find BRAF V600E (5.2%) is the most common mutation in the cancer patient population, TP53 R175H (1.5%) is the most common tumor suppressor mutation, and APC R876X (0.4%) is the most common nonsense mutation. These values differ largely and significantly from what would be found in a typical pan-cancer analysis, where different cancer types are included out of proportion to population level incidence. We present the full ordered lists of population-level abundances for specific missense and nonsense mutations, and we demonstrate the value of these data by further analyzing high priority genes (e.g., TP53, KRAS, BRAF) and pathways (e.g., RTK/RAS, PI3K, and WNT/{beta}-catenin). Overall, this information is a resource that should benefit the basic science, translational, and clinical cancer research communities.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Pan-cancer association of DNA repair deficiencies with whole-genome mutational patterns 97%
- Transcriptional pattern enriched for synaptic signaling is associated with shorter survival of patients with high-grade serous ovarian cancer 94%
- Recurrent disruption of tumour suppressor genes in cancer by somatic mutations in cleavage and polyadenylation signals 94%
Similar papers in this journal
- Total whole-arm chromosome losses predict malignancy in human cancer 95%
- Improved detection of gene fusions by applying statistical methods reveals new oncogenic RNA cancer drivers 94%
- SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status 93%
Similar papers in this journal
- Germline and somatic genetic variants in the p53 pathway interact to affect cancer risk, progression and drug response 96%
- Pan-cancer Drivers are Recurrent Transcriptional Regulatory Heterogeneities in Early-stage Luminal Breast Cancer 95%
- Leveraging Allele-Specific Expression for Therapeutic Response Gene Discovery in Glioblastoma. 94%
Similar papers in this journal
- Copy number losses of oncogenes and gains of tumor suppressor genes generate common driver events of human cancer 97%
- Cross-Cancer Evaluation of Polygenic Risk Scores for 17 Cancer Types in Two Large Cohorts 95%
- A multiscale functional map of somatic mutations in cancer integrating protein structure and network topology 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.